Teleflex Incorporated (NYSE:TFX – Get Free Report) has received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $267.71.
A number of equities research analysts have commented on TFX shares. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $205.00 to $245.00 in a research report on Monday, July 1st. Royal Bank of Canada increased their price objective on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Truist Financial increased their price target on shares of Teleflex from $240.00 to $247.00 and gave the company a “hold” rating in a research note on Monday, August 5th. Finally, Stephens increased their target price on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd.
Read Our Latest Stock Analysis on Teleflex
Insider Transactions at Teleflex
Institutional Investors Weigh In On Teleflex
Institutional investors and hedge funds have recently bought and sold shares of the stock. Riverview Trust Co acquired a new stake in shares of Teleflex in the first quarter worth approximately $31,000. Pineridge Advisors LLC purchased a new stake in shares of Teleflex during the fourth quarter valued at approximately $35,000. Canada Pension Plan Investment Board acquired a new position in shares of Teleflex during the second quarter worth $42,000. GAMMA Investing LLC grew its holdings in Teleflex by 131.1% during the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 97 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in Teleflex by 20,700.0% during the 2nd quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock worth $44,000 after buying an additional 207 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.
Teleflex Price Performance
TFX stock opened at $236.03 on Friday. The business’s fifty day moving average price is $240.18 and its 200 day moving average price is $222.54. Teleflex has a 12-month low of $177.63 and a 12-month high of $257.85. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $11.12 billion, a PE ratio of 42.38, a P/E/G ratio of 2.13 and a beta of 1.16.
Teleflex (NYSE:TFX – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.33 by $0.09. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The business had revenue of $749.70 million during the quarter, compared to analyst estimates of $762.98 million. During the same quarter last year, the firm posted $3.41 earnings per share. The business’s revenue for the quarter was up .9% compared to the same quarter last year. On average, sell-side analysts anticipate that Teleflex will post 13.97 EPS for the current year.
Teleflex Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend was Thursday, August 15th. Teleflex’s dividend payout ratio (DPR) is presently 24.42%.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Further Reading
- Five stocks we like better than Teleflex
- How to invest in marijuana stocks in 7 steps
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- About the Markup Calculator
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.